Altmetrics
Downloads
110
Views
39
Comments
0
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
Submitted:
12 May 2023
Posted:
12 May 2023
You are already at the latest version
Malaysia | Thailand | Taiwan | Vietnam | China | Mauritius | India | Laos | Bangladesh | Total | |
---|---|---|---|---|---|---|---|---|---|---|
Cultivar | 2 | 1 | 1 | 1 | 1 | 6 | ||||
Landrace | 3 | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 17 |
Total | 5 | 5 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 23 |
Name | Abbreviation | Class | RT (min) | MRM Transition |
CID (ev) | Dwell Time (sec) | Calibration Curve Parameters |
---|---|---|---|---|---|---|---|
Progoitrin | PRO | Aliphatic | 5.94 | 387.77 >194.85 | 25 | 0.029 | Y = 8.2526X + 28.1501(r2= 0.961) |
Sinigrin | SIN | Aliphatic | 6.56 | 357.75 >161.84 | 25 | 0.029 | Y = 12.7878X -11.1181 (r2= 0.999) |
Gluconapin | GNA | Aliphatic | 7.78 | 371.74 >258.74 | 25 | 0.029 | Y = 8.36216X +29.5397(r2= 0.994) |
Glucoiberin | GIB | Aliphatic | 7.98 | 421.62 >357.73 | 25 | 0.029 | Y = 33.6632X +446.334(r2= 0.997) |
Epiprogoitrin | EPI | Aliphatic | 8.06 | 387.7 > 258.74 | 25 | 0.029 | Y = 7.4939X -6.76519(r2= 0.999) |
Glucocheirolin | GCR | Aliphatic | 8.38 | 437.71 >258.74 | 25 | 0.029 | Y =20.7762X +39.3608(r2= 0.986) |
Glucoraphanin | GRA | Aliphatic | 8.39 | 435.59 >177.78 | 25 | 0.029 | Y = 25.0808X +60.584(r2= 0.983) |
Glucoraphenin | GRE | Aliphatic | 8.53 | 433.66 >258.81 | 25 | 0.029 | Y = 15.2565X +3.62242(r2= 0.988) |
Glucobrassicanapin | GBN | Aliphatic | 8.60 | 385.71 >258.87 | 25 | 0.029 | Y = 7.2514X +47.2841(r2= 0.992) |
Glucobarbarin | GBB | Aromatic | 8.64 | 437.71 >274.75 | 25 | 0.029 | Y = 9.29915X -0.454779(r2= 0.999) |
Glucoerucin | GER | Aliphatic | 8.73 | 419.69 >258.74 | 25 | 0.029 | Y = 6.77393X +73.6679(r2= 0.984) |
Glucotropaeolin | GTL | Aromatic | 8.88 | 407.72 >258.87 | 25 | 0.029 | Y = 18.2122X -3.93949(r2= 0.999) |
Sinalbin | SNB | Aromatic | 9.10 | 423.62 >258.74 | 25 | 0.029 | Y = 49.7228X -33.0636(r2= 0.999) |
Glucoberteroin | GBE | Aliphatic | 9.18 | 433.72 >275.06 | 25 | 0.029 | Y = 6.09397X +63.1212(r2= 0.997) |
Glucobrassicin | GBC | Indolyl | 9.31 | 446.69 >204.94 | 25 | 0.029 | Y = 6.39827X +2.6232(r2= 0.997) |
Gluconasturtiin | GNS | Aromatic | 9.34 | 421.69 >274.87 | 25 | 0.029 | Y = 4.36109X –90.233(r2= 0.961) |
Glucoraphasatin | GRH | Aromatic | 9.62 | 417.63 >258.81 | 25 | 0.029 | Y = 15.5149X -5.95281(r2= 0.997) |
Variable | Range | Mean | Std. deviation | |
Aliphatic GSLs | Glucoiberin | 0~1.48 | 0.39 | 0.46 |
Sinigrin | 0.16~17.69 | 3.69 | 4.21 | |
Glucocheirolin | 0.08~19.91 | 5.48 | 6.07 | |
Glucoerucin | 0.64~1,983.01 | 227.83 | 562.36 | |
Glucoraphanin | 2.29~569.16 | 166.77 | 179.00 | |
Gluconapin | 117.38~13,111.41 | 2,997.62 | 3,406.77 | |
Progoitrin | 120.20~3,172.65 | 1,430.06 | 899.82 | |
Epiprogoitrin | 72.56~2,728.20 | 1,085.29 | 711.35 | |
Glucoraphasatin | 0.03~9.89 | 0.70 | 2.02 | |
Glucoraphenin | 0.11~9.18 | 1.35 | 2.10 | |
Glucoberteroin | 6.02~3,491.34 | 440.22 | 899.73 | |
Glucobrassicanapin | 148.87~6,830.64 | 1,884.15 | 1,457.35 | |
Total aliphatic | 8,243~18,110.85 | 8,243.54 | 4,557.95 | |
Aromatic GSLs | Glucotropaeolin | 1.83~9.58 | 4.87 | 2.08 |
Gluconasturtiin | 74.28~2,379.24 | 631.28 | 575.41 | |
Glucobarbarin | 0.97~8.04 | 2.94 | 1.71 | |
Sinalbin | 0.04~2.96 | 0.34 | 0.69 | |
Total aromatic | 84.98~2,389.73 | 639.42 | 576.14 | |
Indolic GSLs | Glucobrassicin | 85.15~908.09 | 333.30 | 203.01 |
Total GSLs | 9,216~20,023.79 | 9,216.26 | 4,905.73 |
Chemical Compounds | Class | Hydrolysis Products | Functions |
Gluconapin | Aliphatic | 1-cyano-3,4-etithiobutane |
In Mice ∙ Prevent postprandial hypertriglyceridemia and decrease plasma triglyceride gain [27] In Human ∙ Increase NAD(P)H quinone oxidoreductase 1 (NQO1), glutathione S -transferase A3 and the glutamate–cysteine ligase subunit; (CETP) in Hep G2 Cell [36] |
Glucobrassicanapin | Aliphatic | 4-pentenyl isothiocyanate |
In Gram negative bacteria ∙ Increase antibacterial activity against Aeromonas hydrophila [23] In rat [24] ∙ Decreas release of leukotriene B4 (LTB4) and release of leukotriene B4 (LTB4) from RBL- |
Progoitrin | Aliphatic | Nitrile Crambene (1-cyano-2-hydroxy-3-butene) |
IN human Hep Gsub2 cell; mouse Hepa 1c1c7 cells and mouse H4IIEC3 cells [25] ∙ Increase the activity of quinone reductase resulting in cell cycle arrest In Swiss mice In Swiss mice protect against acute pancreatitis by inducing pancreatic acinar cell apoptosis by activating anti-inflammatory and mitochondrial pathways [25,29] ∙ Decerase acute pancreatitis and activate anti-inflammatory pathway [25] ∙ Activate mitochondrial pathways [29] |
Gluconasturtiin | Aromatic | 2-phenylethyl isothiocyante | The anticancer activity of phenylethyl isothiocyanate, a hydrolyzed product obtained from gluconasturtiin, is excellent as it induces cyto-protective genes mediated by Nrf2 and AhR transcription factors, represses NF-κB, and inhibits both cytochrome P450 and histone deacetylase [37] |
Glucobrassicin | Indolic | Indole-3-carbinol |
In human ∙ Inhibit breast and ovarian cancer [38] ∙ Inhibit apoptosis of osteoporosis and ROS-mediated Nrf2 pathway [30] In rat ∙ Decrease portal hypertension, the severity of mesenteric angiogenesis, and portosystemic collaterals in cirrhosis [39] In mice ∙ Decrease Citrobacter rodentium growth causing acute intestinal inflammation and increase T cell activity [40] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated